• ±ÏÒµÂÛÎĶ¨ÖÆ
    ÄÏÔÁÂÛÎÄÖÐÐÄÌṩ±¾¿Æ/Ñо¿Éú/²©Ê¿±ÏÒµÂÛÎÄ£¬´ÓÌá¸Ù£¬¿ªÌâµ½ºóÆÚÃâ·ÑÐÞ¸Ä,Ãâ·ÑÖ¸µ¼´ð±çµÈ £¬ÁªÏµÈË£ºÎºÀÏʦ£¬µç»°£º13450375436¡£
  • ´úд´ú·¢Ö°³ÆÂÛÎÄ
    ÄÏÔÁÂÛÎÄÖÐÐÄÌṩְ³ÆÂÛÎÄ´úд£¬±¨¸æ×ܽᣬÑݽ²Ö´Ç,ÐĵÃÌå»á,µ³ÍŸ¨µ¼µÈ´úд·þÎñ²¢ÍƼö·¢±íÊ¡¼¶,¹ú¼Ò¼¶,ºËÐÄÔÓÖ¾°ü·¢¡£ÁªÏµQQ:631069747¡£

ApoE»ùÒò¶à̬ÐÔ¡¢hs-CRPÓë¹ÚÐIJ¡µÄÏà¹ØÐÔÑо¿

À´Ô´£º¹ãÎ÷½ÌÓýÌü¿ÎÌ⣨¹ð½Ì¿ÆÑУÛ2006 ×÷Õߣº»ÆÔ¾±ó ºÎÓ¡ÀÙ ·¢±íÓÚ£º2010-01-10 22:31¡¡ µã»÷£º´Î
¡¾¹Ø½¡´Ê¡¿Ïà¹ØÐÔ,Ñо¿,»ùÒò,CHD,CRP,hs,ApoE,and,
¡¾¹Ø¼ü´Ê¡¿ ÔØÖ¬µ°°×E£»»ùÒò¶à̬ÐÔ£»¸ßÃôCª²·´Ó¦µ°°×£»¹ÚÐIJ¡ ¡¾ÕªÒª¡¿ Ä¿µÄ ·ÖÎöÔØÖ¬µ°°×E£¨ApoE£©µÄ»ùÒò¶à̬ÐÔ¡¢¸ßÃôCª²·´Ó¦µ°°×£¨hsª²CRP£©º¬Á¿Óë¹ÚÐIJ¡µÄÏà¹ØÐÔ¡£·½·¨ ²ÉÓ÷ÓÂȷ³éÌáºËËá·¨´ÓÄýѪ¿éÖзÖÀë,Ó¦ÓþۺÏøÁ´·´Ó¦£¨PCR£©£¬Hha1ÄÚÇÐøÏû»¯·¨¶Ô94Àý¹ÚÐÄ

9ApoE»ùÒò¶à̬ÐÔ¡¢hsª²CRPÓë¹ÚÐIJ¡µÄÏà¹ØÐÔÑо¿)The correlation of the polymorphism of apolipoprotein E and high sensitivity Cª²reactive¡¡protein  for coronary heart disease

¡¡¡¡HUANG Yueª²Bin£¬HE Yinª²Lei.

¡¡¡¡Institute of Laboratory Medicine, Youjiang Nationalities Medical College, Baise 533000, Guangxi, China

¡¡¡¡¡¾Abstract¡¿  Objective  To analyze the polymorphism of apolipoprotein E (ApoE), and high sensitivity Cª²reactive¡¡protein (hsª²CRP) levels and the relevance of coronary heart disease (CHD). Methods  Phenol chloroform extraction was used to get the DNA from the isolated blocks blood coagulation. Polymerase chain reaction, Hhal endonuclease digestion were used to test  the 94 cases of CHD patients and 100 healthy control group ApoE polymorphism. Hsª²CRP level was measured by immune latex transmission turbidity. Results  ¢Ù ApoE allele frequency: compared with the control group, ε2 allele frequency decreased significantly (P=0.01) in CHD group, ε4 allele frequency increased (P=0.005). ¢Ú Serum hsª²CRP concentration in CHD group was significantly higher than that of control grooup (P£¼0.05), but there was no significant difference between different alleles on hsª²CRP. Conclusions  The ApoE gene polymorphism and serum hsª²CRP are the sensitive and valuable indicators, which can predict the the risk of cardiovascular disease.
   
¡¡¡¡¡¾Key words¡¿  Apolipoprotein E; Genetic polymorphism; High sensitivity Cª²reactive¡¡protein; Coronary heart disease

¡¡¡¡9ApoE»ùÒò¶à̬ÐÔ¡¢hsª²CRPÓë¹ÚÐIJ¡µÄÏà¹ØÐÔÑо¿)¹ÚÐIJ¡(CHD)Êdz£¼ûµÄ¶à·¢²¡,ÊÇÐÄѪ¹Üϵͳ¼²²¡³£¼ûµÄËÀÍöÔ­ÒòÖ®Ò»¡£Ñо¿ÈÏΪ£¬ÔØÖ¬µ°°×E£¨ApoE£©»ùÒò¶à̬ÐÔÓëCHDÓÐÒ»¶¨µÄÏà¹ØÐÔ¡²1¡«3¡³£¬¹Ú×´¶¯ÂöÖàÑùÓ²»¯²¢²»ÊÇÒ»ÖÖ¼òµ¥µÄÖ¬ÖʳÁ»ý¼²²¡,Ñ×Ö¢ÊÇÆäÖØÒªÌØÕ÷,Òò´Ë,CHDÊÇÒ»ÖÖÑ×ÐÔ¼²²¡¡£¸ßÃôC·´Ó¦µ°°×(hsª²CRP)ÓëCHDµÄ¹ØϵÖð½¥±»ÁÙ´²¹ã·º¹Ø×¢¡£±¾ÎĶÔ94ÀýCHD»¼ÕßѪҺ½øÐÐAopE»ùÒò¶à̬ÐÔ¼°hsª²CRPŨ¶È¼ì²â£¬Ö¼ÔÚÑо¿ÑªÇåhsª²CRP¡¢ApoE»ùÒò¶à̬ÐÔÓëCHDµÄÏà¹ØÐÔ¡£

¡¡¡¡1  ¶ÔÏóÓë·½·¨

¡¡¡¡1.1  Ñо¿¶ÔÏó  CHD×é94Àý£¬ÆäÖÐ׳×å42Àý£¬ºº×å52Àý£¬¾ùΪÓÒ½­Ãñ×åҽѧԺ¸½ÊôÒ½ÔºÐÄÄÚ¿Æ2007Äê1ÔÂÖÁ2007Äê8ÔÂסԺCHD»¼Õߣ»ÄÐ59Àý£¬Å®35Àý£¬ÄêÁä44¡«77Ë꣬ƽ¾ù£¨60±12.7£©Ë꣬ȫ²¿·ûºÏ1979ÄêÊÀ½çÎÀÉú×éÖ¯ÐÞ¶©µÄCHDÕï¶Ï±ê×¼¡£¶ÔÕÕ×é100Àý£¬¾ùΪͬÆÚסԺµÄ·ÇCHD»¼Õߣ¬²¢ÅųýÐÄÄÔѪ¹Ü¼²²¡¼°¸Î¡¢Éö¡¢ÄÚ·ÖÃÚµÈÓ°ÏìÖ¬ÖÊ´úлµÄ¼²²¡£»ÄÐ56Àý£¬Å®44Àý£¬ÄêÁä45¡«80Ë꣬ƽ¾ù£¨65±10.8£©Ëê¡£ËùÓÐÊÜÊÔÕßÔÚʵÑéÇ°¾ùÖªÇéͬÒâ×ÔÔ¸²Î¼Ó±¾ÊµÑé¡£

¡¡¡¡1.2  ·½·¨9ApoE»ùÒò¶à̬ÐÔ¡¢hsª²CRPÓë¹ÚÐIJ¡µÄÏà¹ØÐÔÑо¿)

¡¡¡¡1.2.1  ApoE»ùÒò¶à̬ÐԵļì²â

¡¡¡¡1.2.1.1  DNAÌáÈ¡  ²É¿Õ¸¹¾²ÂöѪ2.5¡«3.0 ml£¬EDTA¿¹Äý£¬ÓõÍÉøÈÜѪ·Óª²Âȷ³éÌá°×ϸ°ûºËËáDNA£¬Ë«ÕôË®Èܽâºó×÷Ϊģ°å¡£

¡¡¡¡1.2.1.2  ¾ÛºÏøÁ´·´Ó¦£¨PCR£©À©Ôö  ÒýÎïÉè¼Æ²Î¿¼ÎÄÏס²4¡³£ºÒýÎïÐòÁУ¬ÉÏÓÎÒýÎïP1Ϊ£º 5′ª²AAC AAC TGA CCC CGG TGG CGª²3′,ÏÂÓÎÒýÎïP2Ϊ£º5′ª²ATG GCG CTG AGG CCG CGC TCª²3′,ÓÉÉîÛÚÆ¥»ù¹«Ë¾ºÏ³É¡£PCR·´Ó¦Ìåϵ°üÀ¨10×dNTP(¸÷10 mmol/L)1.0 μl,ÒýÎïP1ºÍP2¸÷0.8 μl£¬¶þ¼×»ùÑÇí¿5 μl£¬DNAÄ£°å1.0 μl£¬Tag DNA¾ÛºÏø2 U£¬¼ÓË«ÕôË®ÖÁ40 μl£¬»ìÔȼ´¿É¡£PCR·´Ó¦Ìõ¼þ£º95¡æÔ¤±äÐÔ2 min£¬È»ºó95¡æ 60 s£¬56¡æ 30 s£¬72¡æ 30 s,¹²35¸öÑ­»·¡£ÓÃ20 g/LÇíÖ¬ÌÇÄý½ºµçӾȷ¶¨ÌØÒìÐÔÀ©Ôö²úÎï(292 bpƬ¶Î)¡£PCR²úÎïµÄøÇз´Ó¦:øÇз´Ó¦Ìåϵ°üÀ¨À©Ôö²úÎï10 U,10×Buffer 5 μl,ÏÞÖÆÐÔÄÚÇÐøHha1 10 U,¼ÓË«ÕôË®ÖÁ×ÜÌå»ý40 μl,ÖÃÓÚ37¡æÎÂÓý3 h¡£

¡¡¡¡1.2.1.3  ApoE»ùÒò·ÖÐÍ  øÇвúÎï¾­100 g/L¾Û±ûõ£°·Äý½ºµçÓ¾,EBȾɫºó×ÏÍâÏßµÆϹ۲ì,ÒÔpBR322DNA/HaeΪ·Ö×Ó±êÖ¾Îï,Åжϱê×¼²ÎÕÕÎÄÏס²5¡³·½·¨¡£

¡¡¡¡1.2.2  hsª²CRP¼ì²â  ²É¿Õ¸¹¾²ÂöѪ1.0 ml£¬·ÖÀëѪÇ壬²ÉÓÃÈÕÁ¢7060Éú»¯È«×Ô¶¯ÒÇ£¬ÒÔÈ齺ÔöÇ¿ÃâÒß͸Éä±È×Ç·¨¼ì²â¡£

¡¡¡¡1.3  ͳ¼Æѧ·ÖÎö  Ñ¡ÓÃSPSS10.0Èí¼þ½øÐÐt¼ìÑé¡£

¡¡¡¡2  ½á¹û9ApoE»ùÒò¶à̬ÐÔ¡¢hsª²CRPÓë¹ÚÐIJ¡µÄÏà¹ØÐÔÑо¿)

¡¡¡¡2.1  ApoEµÄ»ùÒòÐͺ͵Èλ»ùÒòƵÂʱȽϼ°Æä¶àëÄÐÔÓëѪÇåhsª²CRPº¬Á¿¹Øϵ  ¼û±í1£¬±í2¡£Óë¶ÔÕÕ×é±È½Ï£¬CHD×éºÍε2µÈλ»ùÒòƵÂÊÃ÷ÏÔ½µµÍ(P£¼0.01)£¬ε4µÈλ»ùÒòƵÂÊÃ÷ÏÔÉý¸ß(P£¼0.05)¡£CHD×éhsª²CRPÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×飬¶ø¸÷µÈλ»ùÒò×é¼äÎÞÏÔÖø²îÒì¡£(ÔðÈα༭£ºÄÏÔÁÂÛÎÄÖÐÐÄ)תÌùÓÚÄÏÔÁÂÛÎÄÖÐÐÄ: http://www.nylw.net(ÄÏÔÁÂÛÎÄÖÐÐÄ__´úд´ú·¢ÂÛÎÄ_±ÏÒµÂÛÎÄ´øд_¹ãÖÝÖ°³ÆÂÛÎÄ´ú·¢_¹ãÖÝÂÛÎÄÍø£©

¶¥Ò»ÏÂ
(0)
0%
²ÈÒ»ÏÂ
(0)
0%


°æȨÉùÃ÷£ºÒò±¾ÎľùÀ´×ÔÓÚÍøÂ磬Èç¹ûÓаæȨ·½ÃæÇÖ·¸,Ç뼰ʱÁªÏµ±¾Õ¾É¾³ý.